Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Launched by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. · Aug 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Anlotinib hydrochloride capsules to see how effective and safe it is for treating patients with a specific type of thyroid cancer known as locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma. This means the trial is looking at patients whose cancer has not responded to radioactive iodine treatment and is either spreading or is difficult to control. The researchers aim to gather information from a broad group of patients to better understand the treatment experience in real-world settings.

To participate in this trial, patients should be between 18 and 70 years old, have a confirmed diagnosis of the specified type of thyroid cancer, and meet certain health criteria, including having measurable disease and good overall health. Participants can expect regular check-ups and monitoring during the study to assess how well the medication works and any side effects they might experience. It's important to note that patients who have had other specific cancer treatments or have certain serious health conditions may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients voluntarily participate in this study, sign the informed consent form and had good compliance;
• • Aged 18 \~ 70 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0\~1; more than 6 months of expected survival ;
• • Histopathologically confirmed locally advanced or metastatic differentiated thyroid cancer, radiographically documented disease progression within 18 months of absence of radioactive iodine (RAI) therapy;
• * Meet any of the following:
• 1. Lesions were not iodine-avid: no RAI uptake was confirmed after RAI scan in the presence of a low-iodine diet, adequate thyroid stimulating hormone (TSH) elevation (≥ 30 mIU/L). The definition of no iodine uptake:
• • 1. no iodine uptake initially;
• • 2. exist of iodine uptake initially while lost subsequently;
• • 3. partially uptake;
• • 4. progression disease despite iodine uptake.
• • 2. The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months.
• • 3. Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;
• • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
• * Major organ functions meet the following criteria within 7 days prior to treatment:
• 1. Blood routine test criteria (14 days without blood transfusion):
• • 1. Hemoglobin (HB) ≥ 85 g/L;
• • 2. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L;
• • 3. Platelet (PLT) ≥ 80 × 10\^9/L
• 2. Biochemical tests need to meet the following criteria:
• • 1. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN);
• • 2. Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2 .5×ULN, ALT and AS if liver metastases T ≤ 5 ×ULN;
• • 3. Serum creatinine (Cr) ≤ 1 .5 ×ULN or creatinine clearance (CCr) ≥ 60 Ml/min;
• • Females of childbearing potential should agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating patients; and males should agree to use contraceptive measures during the study and within 6 months after the end of the study period.
• Exclusion Criteria:
• * Comorbidities and medical history:
• • 1. A history of or concurrent with other malignancies within the past 3 years. Patients were eligible if they had disease-free survival (DFS) for 5 consecutive years in other malignancies treated by single surgery; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\];
• • 2. Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment;
• 3. Subjects with any severe and/or uncontrolled illness, including:
• • 1. Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including Corrected QT Interval (QTc)≥450ms(male), QTc≥ 470ms(female)) and ≥ grade 2 congestive heart failure (NYHA classification);
• • 2. Severe active or uncontrolled infection (≥ grade 2 infection according to Common Terminology Criteria for Adverse Events (CTCAE) );
• • 3. Renal failure requiring hemodialysis or peritoneal dialysis;
• • Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study, or patients who are considered to be unsuitable for enrollment for other reasons according to the judgment of the investigators.
• • patients with previous treatment with anlotinib hydrochloride capsules or similar vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, Cabozantinib, lenvatinib, sunitinib, or sorafenib, etc.;